Clinical and Translational Research
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2023; 11(1): 92-103
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.92
Identification of a four-miRNA signature predicts the prognosis of papillary thyroid cancer
Fan Yang, Yi-Li Zhou
Fan Yang, Yi-Li Zhou, Department of Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Author contributions: Yang F and Zhou YL designed the research study, performed the research, and wrote the manuscript; all authors have read and approved the final manuscript.
Supported by the Foundation of Wenzhou Municipal Science and Technology Bureau, No. Y20190209 and No. Y2020739; and the Hospital Research Incubation Program, No. FHY2019075.
Institutional review board statement: The study was reviewed and approved by Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University (Approval No. 2022-69).
Informed consent statement: Patients were not required to give informed consent to the study because this study is a bioinformatics analysis and the required patient information was downloaded from the TCGA database.
Conflict-of-interest statement: All other authors have nothing to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi-Li Zhou, MD, PhD, Doctor, Department of Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical University, South of Bai-Xiang Street, Ou-Hai District, Wenzhou 325000, Zhejiang Province, China. yilistar@163.com
Received: September 28, 2022
Peer-review started: September 28, 2022
First decision: November 4, 2022
Revised: November 10, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 6, 2023
ARTICLE HIGHLIGHTS
Research background

Papillary thyroid cancer is a highly heterogeneous disease and therefore molecular markers need to be established to predict its prognosis.

Research motivation

The present study aims to explore novel markers consisting of microRNA (miRNA)-associated signatures for papillary thyroid cancer (PTC) prognostication.

Research objectives

To establish a practical tool has satisfying potential in stratifying PTC patients and individualized therapy to avoid overtreatment or inadequate treatment.

Research methods

In this study, a panel of four miRNAs is generated as a prognostic signature, which is then tested in PTC patients.

Research results

The panel of four miRNAs could reliably distinguished PTC patients from high and low risk with a significant difference in the overall survival.

Research conclusions

More intensive treatment and closer follow-ups for high-risk PTC patients are recommended.

Research perspectives

Our prognostic signature contributed to individualized therapy to avoid overtreatment or inadequate treatment.